News Posted on July 6, 2026 Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027 Interim analysis to be conducted under an FDA- and EMA-agreed protocol Go to Source By sf-admin